MENU
DNTH
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Dianthus Therapeutics (DNTH) Ownership - Who owns Dianthus Therapeutics?
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies... Show more
Profile
Industry
N/A
Address
7 Times Square
Phone
+1 929 999-4055
Employees
53
Web
https://www.dianthustx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
573.76M
P/E Ratio
3.24
Total Cash
275.24M
Projected Growth
N/A
Total Debt
1.49M
Revenue
6.24M
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
8.57
Total Debt/Equity
N/A
Revenue/Share
0.19 USD as % of share price
Fundamentals
DNTH
Capitalization
574M
P/E Ratio
3.24
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
275M
Total Cash/Share
8.57
Total Debt
1.49M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.19%
Revenue
6.24M
ROE
N/A
Book Value
352M
P/B Ratio
1.63
Cash Flow
N/A
Earnings
-2.55
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
31K
Current Ratio
15.22
Current Revenue Per Employee
17000.00
Dividends Per Share - Security
N/A
EBITDA
-101.45M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-30.71
Shares Held By Institutions
966M
Shares Outstanding - Current
32.1M
Total Liabilities
21.5M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-22.798
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
7 Times Square
Phone
+1 929 999-4055
Employees
53
Web
https://www.dianthustx.com